
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4728869/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiology of Aging, 2011, 32, 763-777.	3.1	413
2	Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Advanced Drug Delivery Reviews, 2008, 60, 1463-1470.	13.7	288
3	Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Research Reviews, 1997, 23, 134-143.	9.0	257
4	Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. , 2007, 113, 154-164.		248
5	Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Research, 2002, 953, 135-143.	2.2	215
6	Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. Journal of Neurochemistry, 2005, 92, 255-263.	3.9	199
7	Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer's disease. Scientific Reports, 2016, 6, 31450.	3.3	186
8	Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1360, 17-29.	3.8	160
9	Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Archives of Gerontology and Geriatrics, 2001, 32, 275-282.	3.0	158
10	Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. Journal of Alzheimer's Disease, 2002, 4, 193-201.	2.6	155
11	Age- and Stage-dependent Accumulation of Advanced Glycation End Products in Intracellular Deposits in Normal and Alzheimer's Disease Brains. Cerebral Cortex, 2004, 15, 211-220.	2.9	152
12	Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Research, 2001, 920, 32-40.	2.2	151
13	Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer′s disease. Neural Regeneration Research, 2015, 10, 1181.	3.0	151
14	Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease. Neurochemistry International, 2016, 95, 63-74.	3.8	145
15	Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. European Journal of Nutrition, 2018, 57, 929-938.	3.9	142
16	Activated astroglia during chronic inflammation in Alzheimer's disease—Do they neglect their neurosupportive roles?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 690, 40-49.	1.0	139
17	Methylglyoxal, Glyoxal, and Their Detoxification in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2005, 1043, 211-216.	3.8	132
18	Plant polyphenols as inhibitors of NF-κB induced cytokine productionââ,¬â€a potential anti-inflammatory treatment for Alzheimer's disease?. Frontiers in Molecular Neuroscience, 2015, 8, 24.	2.9	115

#	Article	IF	CITATIONS
19	Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells. Redox Biology, 2013, 1, 441-445.	9.0	113
20	AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?. Biogerontology, 2001, 2, 19-34.	3.9	110
21	Amino acid specificity of glycation and protein–AGE crosslinking reactivities determined with a dipeptide SPOT library. Nature Biotechnology, 1999, 17, 1006-1010.	17.5	108
22	Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids, 2012, 42, 1221-1236.	2.7	105
23	Transition metal-mediated glycoxidation accelerates cross-linking of β-amyloid peptide. FEBS Journal, 2000, 267, 4171-4178.	0.2	101
24	Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiology of Aging, 2007, 28, 29-41.	3.1	101
25	Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. European Journal of Neuroscience, 2001, 14, 1961-1967.	2.6	100
26	Effect of Pseudophosphorylation and Cross-linking by Lipid Peroxidation and Advanced Glycation End Product Precursors on Tau Aggregation and Filament Formation. Journal of Biological Chemistry, 2007, 282, 6984-6991.	3.4	100
27	High bioavailability curcumin: an anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation. Archives of Toxicology, 2017, 91, 1623-1634.	4.2	94
28	Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). Journal of Neurochemistry, 2003, 87, 44-55.	3.9	93
29	Anti-inflammatory activity of cinnamon (C. zeylanicum and C. cassia) extracts – identification of E-cinnamaldehyde and o-methoxy cinnamaldehyde as the most potent bioactive compounds. Food and Function, 2015, 6, 910-919.	4.6	93
30	Advanced glycation end products as biomarkers and gerontotoxins – A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?. Experimental Gerontology, 2010, 45, 744-751.	2.8	89
31	β-Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon -γ and â€ĩadvanced glycation endproducts' in a murine microglia cell line. European Journal of Neuroscience, 2003, 17, 813-821.	2.6	88
32	Chronic Neuroinflammation in Alzheimer's Disease: New Perspectives on Animal Models and Promising Candidate Drugs. BioMed Research International, 2014, 2014, 1-10.	1.9	88
33	Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence. Journal of Molecular Neuroscience, 2017, 61, 289-304.	2.3	83
34	Methylglyoxal, Cognitive Function and Cerebral Atrophy in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 68-73.	3.6	78
35	Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds. Pharmacological Research, 2016, 103, 80-94.	7.1	78
36	Activated astrocytes: a therapeutic target in Alzheimer's disease?. Expert Review of Neurotherapeutics, 2009, 9, 1585-1594.	2.8	73

#	Article	IF	CITATIONS
37	Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells. Experimental Brain Research, 2003, 150, 1-8.	1.5	72
38	Investigations on oxidative stress and therapeutical implications in dementia. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S68-S73.	3.2	71
39	Type 2 Diabetes, Skin Autofluorescence, and Brain Atrophy. Diabetes, 2015, 64, 279-283.	0.6	71
40	The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotoxicity Research, 2005, 7, 95-101.	2.7	69
41	Mapping of β-adrenoceptor coupling domains to Gs -protein by site-specific synthetic peptides. FEBS Letters, 1989, 254, 89-93.	2.8	67
42	Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain. Neurobiology of Aging, 2015, 36, 753-761.	3.1	65
43	Plantâ€derived polyphenols attenuate lipopolysaccharideâ€induced nitric oxide and tumour necrosis factor production in murine microglia and macrophages. Molecular Nutrition and Food Research, 2008, 52, 427-438.	3.3	64
44	Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease – A Translational Perspective. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1175-1191.	1.4	58
45	Identification of a Gs-protein coupling domain to the β-aderenoceptor using site-specific synthetic peptides. FEBS Letters, 1990, 261, 294-298.	2.8	57
46	<i>Inflammation and the Redoxâ€sensitive AGE–RAGE Pathway as a Therapeutic Target in Alzheimer's Disease</i> . Annals of the New York Academy of Sciences, 2008, 1126, 147-151.	3.8	57
47	Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radical Biology and Medicine, 2006, 40, 779-790.	2.9	53
48	Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine, 2008, 41, 198-203.	3.2	49
49	Chronic Inflammation Alters Production and Release of Glutathione and Related Thiols in Human U373 Astroglial Cells. Cellular and Molecular Neurobiology, 2013, 33, 19-30.	3.3	45
50	Evidence For and Against a Pathogenic Role of Reduced γ-Secretase Activity in Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 52, 781-799.	2.6	44
51	Neuroprotection of Neuro2a cells and the cytokine suppressive and anti-inflammatory mode of action of resveratrol in activated RAW264.7 macrophages and C8–B4 microglia. Neurochemistry International, 2016, 95, 46-54.	3.8	44
52	Chronic Microglial Activation in the GFAP-IL6 Mouse Contributes to Age-Dependent Cerebellar Volume Loss and Impairment in Motor Function. Frontiers in Neuroscience, 2019, 13, 303.	2.8	42
53	Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. Journal of Alzheimer's Disease, 2003, 5, 25-30.	2.6	41
54	An in vitro study of anti-inflammatory activity of standardised Andrographis paniculata extracts and pure andrographolide. BMC Complementary and Alternative Medicine, 2015, 15, 18.	3.7	41

#	Article	IF	CITATIONS
55	Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. Neuroscience Letters, 2001, 312, 29-32.	2.1	40
56	Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology. Journal of Neurochemistry, 2004, 86, 283-289.	3.9	39
57	Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and α-lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?. Neurobiology of Disease, 2019, 124, 505-519.	4.4	36
58	Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts―with "advanced lipoxidation endproducts― Neurobiology of Aging, 2005, 26, 465-474.	3.1	35
59	In search of an anti-inflammatory drug for Alzheimer disease. Nature Reviews Neurology, 2020, 16, 131-132.	10.1	35
60	Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4224-4231.	3.6	32
61	Determination of anti-inflammatory activities of standardised preparations of plant- and mushroom-based foods. European Journal of Nutrition, 2014, 53, 335-343.	3.9	31
62	Advanced Glycation Endproducts Induce Changes in Glucose Consumption, Lactate Production, and ATP Levels in SH-SY5Y Neuroblastoma Cells by a Redox-Sensitive Mechanism. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1307-1313.	4.3	27
63	Revelation of molecular basis for chromium toxicity by phenotypes of Saccharomyces cerevisiae gene deletion mutants. Metallomics, 2016, 8, 542-550.	2.4	27
64	Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines. CNS Drugs, 2019, 33, 457-480.	5.9	27
65	A Versatile High Throughput Screening System for the Simultaneous Identification of Anti-Inflammatory and Neuroprotective Compounds. Journal of Alzheimer's Disease, 2010, 19, 451-464.	2.6	26
66	Evaluation of Phytosomal Curcumin as an Anti-inflammatory Agent for Chronic Glial Activation in the GFAP-IL6 Mouse Model. Frontiers in Neuroscience, 2020, 14, 170.	2.8	25
67	Hydrogen peroxide mediates pro-inflammatory cell-to-cell signaling: a new therapeutic target for inflammation?. Neural Regeneration Research, 2019, 14, 1430.	3.0	25
68	Medicinal Plants of the Australian Aboriginal Dharawal People Exhibiting Anti-Inflammatory Activity. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-8.	1.2	24
69	S-allyl-l-cysteine and isoliquiritigenin improve mitochondrial function in cellular models of oxidative and nitrosative stress. Food Chemistry, 2016, 194, 843-848.	8.2	24
70	A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. American Journal of Obstetrics and Gynecology, 2019, 221, 255.e1-255.e9.	1.3	24
71	Anti-Inflammatory Chemical Profiling of the Australian Rainforest Tree Alphitonia petriei (Rhamnaceae). Molecules, 2016, 21, 1521.	3.8	23
72	Spatial Memory and Microglia Activation in a Mouse Model of Chronic Neuroinflammation and the Anti-inflammatory Effects of Apigenin. Frontiers in Neuroscience, 2021, 15, 699329.	2.8	23

#	Article	IF	CITATIONS
73	Molecular insight into arsenic toxicity via the genome-wide deletion mutant screening of Saccharomyces cerevisiae. Metallomics, 2016, 8, 228-235.	2.4	21
74	Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression. Frontiers in Nutrition, 2021, 8, 669846.	3.7	21
75	Effects of a solid lipid curcumin particle formulation on chronic activation of microglia and astroglia in the GFAP-IL6 mouse model. Scientific Reports, 2020, 10, 2365.	3.3	20
76	Determination of glyoxal and methylglyoxal in serum by UHPLC coupled with fluorescence detection. Analytical Biochemistry, 2019, 573, 51-66.	2.4	19
77	Bacopamonnieri (L.) exerts anti-inflammatory effects on cells of the innate immune system in vitro. Food and Function, 2014, 5, 517-520.	4.6	18
78	The reciprocal EC50 value as a convenient measure of the potency of a compound in bioactivity-guided purification of natural products. Fìtoterapìâ, 2020, 143, 104598.	2.2	18
79	Activation of Macrophages and Microglia by Interferonâ€"î³ and Lipopolysaccharide Increases Methylglyoxal Production: A New Mechanism in the Development of Vascular Complications and Cognitive Decline in Type 2 Diabetes Mellitus?. Journal of Alzheimer's Disease, 2017, 59, 467-479.	2.6	17
80	Synergistic Protective Effect of Curcumin and Resveratrol against Oxidative Stress in Endothelial EAhy926 Cells. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-13.	1.2	14
81	Anti-inflammatory activity of prenyl and geranyloxy furanocoumarins from Citrus garrawayi (Rutaceae). Phytochemistry Letters, 2018, 27, 197-202.	1.2	12
82	Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice. Pharmaceutical Research, 2018, 35, 22.	3.5	11
83	The differential impact of acute microglia activation on the excitability of cholinergic neurons in the mouse medial septum. Brain Structure and Function, 2019, 224, 2297-2309.	2.3	11
84	Synergistic Anti-Inflammatory Activity of Ginger and Turmeric Extracts in Inhibiting Lipopolysaccharide and Interferon-γ-Induced Proinflammatory Mediators. Molecules, 2022, 27, 3877.	3.8	11
85	The effect of aging and chronic microglia activation on the morphology and numbers of the cerebellar Purkinje cells. Neuroscience Letters, 2021, 751, 135807.	2.1	9
86	Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease. Journal of Neural Transmission, 2022, 129, 755-771.	2.8	9
87	Proenergetic effects of resveratrol in the murine neuronal cell line Neuro2a. Molecular Nutrition and Food Research, 2013, 57, 1901-1907.	3.3	8
88	Costatamins A – C, new 4-phenylcoumarins with anti-inflammatory activity from the Australian woodland tree Angophora costata (Myrtaceae). Fìtoterapìâ, 2019, 133, 171-174.	2.2	8
89	Potential anti-neuroinflammatory compounds from Australian plants – A review. Neurochemistry International, 2021, 142, 104897.	3.8	8
90	Influence of the fat/carbohydrate component of snack food on energy intake pattern and reinforcing properties in rodents. Behavioural Brain Research, 2019, 364, 328-333.	2.2	7

#	Article	IF	CITATIONS
91	Ternstroenols A – E: Undescribed pentacyclic triterpenoids from the Australian rainforest plant Ternstroemia cherryi. Phytochemistry, 2020, 176, 112426.	2.9	6
92	The Effects of Different Isocaloric Oral Nutrient Solutions on Psychophysical, Metabolic, Cognitive, and Olfactory Function in Young Male Subjects. Frontiers in Psychology, 2017, 8, 1988.	2.1	5
93	Ternstroenol F: a new pentacyclic triterpenoid saponin isolated from the Australian rainforest plant <i>Ternstroemia cherryi</i> . Natural Product Research, 2023, 37, 2421-2426.	1.8	5
94	Eupomatenes A – E: Neolignans isolated from the leaves of Australian rainforest plant Eupomatia laurina. Fìtoterapìâ, 2021, 153, 104972.	2.2	3
95	Mulgravanols A and B, rare oxidized xanthenes and a new phloroglucinol isolated from the Australian rainforest plant Waterhousea mulgraveana (Myrtaceae). FA¬toterapA¬A¢, 2020, 143, 104595.	2.2	2
96	Identification of tetragocarbone C and sideroxylin as the most potent anti-inflammatory components of Syncarpia glomulifera. Fìtoterapìâ, 2021, 150, 104843.	2.2	2
97	Acronyols A and B, new anti-inflammatory prenylated phloroglucinols from the fruits of <i>Acronychia crassipetala</i> . Natural Product Research, 2022, 36, 4358-4364.	1.8	2
98	The Effects of a Normal Rate versus a Slow Intervalled Rate of Oral Nutrient Intake and Intravenous Low Rate Macronutrient Application on Psychophysical Function – Two Pilot Studies. Frontiers in Psychology, 2017, 8, 1031.	2.1	1
99	A New Anti-inflammatory Phenolic Monosaccharide from the Australian Native Rainforest Plant Elaeocarpus Eumundi. Natural Product Communications, 2018, 13, 1934578X1801300.	0.5	1
100	Identification of Nrf2 activators from the roots of Valeriana officinalis. Planta Medica, 0, , .	1.3	0